ClinicalTrials.gg
RecruitingNCT05626712CREATE-1Updated Feb 19, 2026

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

A Phase 1/2 interventional study of CELZ-201 Administration and Control Group in Type 1 Diabetes and Diabetes Mellitus, Type 1, sponsored by Creative Medical Technology Holdings Inc. Recruiting at 1 site in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Creative Medical Technology Holdings Inc · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
916th of 1,242
18 · median 40
Started
2023
with 65 others
Phase 1/2
59 of 1,458
8 open now
Primary completion
2027-01
later than 85 of 256 live
Registered
1,204th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 916th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 66 that started in 2023, is one of 59 in phase 1/2, reaches primary completion later than 85 of the 256 other live ones, and was the 1,204th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).

Read the detailed description

The proposed study is a Phase I/IIa randomized, controlled clinical trial to evaluate CELZ-201 therapy as an intervention for the treatment of recent onset Type 1 Diabetes. The objective is to determine the safety and efficacy of CELZ-201 administration, based on the timing and dose of CELZ-201 treatment. Subjects who meet eligibility criteria will be randomized to treatment or control groups, in a 2:1 ratio. Subjects in the Group I (Treatment Group, n=12) will receive standard of care for type 1 diabetes and CELZ-201 within 1 month from enrollment (within 1 year of diagnosis). Subjects in Group II (Control Arm, n=6) and will receive enhanced standard of care for type 1 diabetes.

03

Conditions studied

  • Type 1 Diabetes
  • Diabetes Mellitus, Type 1

Keywords

  • Recent Onset Type 1 Diabetes
  • Adult Onset Type 1 Diabetes
  • Type 1 Diabetes
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be able to understand and provide signed .
  2. Males and females, 18-35 years of age.
  3. Diagnosis of T1D within 1 year, with stimulated C-peptide peak level >0.6 ng/mL as assessed by 4-hour MMTT at the time of Visit 0 (screening).
  4. Diagnosed with T1D, according to ADA standard criteria, and confirmed by positivity to at least two islet autoantibodies, GAD65, IA-2, or ZnT8.
  5. Mentally stable and able to comply with the procedures of the study protocol
  6. Subjects must be willing to comply with "standard-of-care" diabetes management.
  7. Subjects with >80 ml/min/1.73m2
  8. Female subjects of must have a negative pregnancy test upon study entry.
  9. Female (and male) subjects with must agree to use two FDA approved methods of for the entire duration of the study.

    Potential subjects of childbearing potential should agree to use effective contraception for the entire 2-year period.

  10. Adequate venous access to support study required blood draws.

Exclusion criteria

Exclusion Criteria:

  1. Inability or unwillingness of a subject to give written or comply with study protocol.
  2. >28 kg/m.
  3. > 9%
  4. Subjects with poorly controlled hypertension as defined by systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg.
  5. Subjects with any history of cardiac disease, including but not limited to myocardial infarction, uncompensated heart failure, fluid overload, as well as any abnormality identified on prior cardiac stress test, angiogram evaluation, or echocardiogram.
  6. Subjects with liver disease, portal hypertension, any coagulopathy (including history of Factor V deficiency) or long-term anti-coagulant therapy (except low-dose aspirin). Other hepatic conditions including hepatic anatomic abnormalities or variants that would place the individual at increased risk in the judgment of the investigator are also considered exclusionary.
  7. Symptomatic cholecystolithiasis; acute or chronic pancreatitis; or current symptomatic peptic ulcer disease.
  8. Subjects with uncontrolled thyroid disease: thyroid stimulating hormone \<0.3 mU/L or >5 mU/L; free T4 \<5.0 ug/dL or >11.0 ug/dL.
  9. Any of the following laboratory findings: \<11.5 g/dL (females) or \<13.2 g/dL (males); leukocytes \<3,000/μL; neutrophils \<1,500/μL; lymphocytes \<800/μL; \<100,000/μL; elevation in and ALT >2 x (upper limit of normal); LDL cholesterol >160; Triglycerides >3 x ULN; total >1.5 x ULN.
  10. Screening laboratory evidence consistent with significant chronic active infection (i.e.., and C, tuberculosis, and ), and IGRA Tuberculosis (Tb) test during screening
  11. Ongoing acute infections, e.g., acute respiratory tract, urinary tract, or gastrointestinal tract infections.
  12. Subjects with eating disorders.
  13. Ongoing or anticipated use of diabetes medications other than insulin.
  14. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 7 days of screening.
  15. Recent recipient of any licensed or (s) within 6 weeks of randomization.
  16. Patients who have participated in previous clinical studies, other than observational studies, will be excluded.
  17. Concomitant therapy with drugs, immunomodulators, or cytotoxic agents, or previous therapy less than 3 months from randomization.
  18. History or diagnosis of with the exception of a history of localized basal or squamous cell carcinoma.
  19. Any history of gastroparesis or other severe gastrointestinal disease.
  20. Presence of an allograft.
  21. Diagnosed or self-reported drug or alcohol abuse.
  22. An individual who has a medical, psychological or social condition that, in the opinion of the Principal Investigator, would interfere with safe and proper completion of the trial.
  23. Pregnancy or ongoing breastfeeding for women; unwillingness or inability of both females and males of childbearing age to use a reliable and effective form of , for the entire 2-year duration of the study.
  24. Inability to perform any of the assessments required for endpoint analysis.
  25. Known history of serious allergic reactions, including anaphylaxis to CELZ-201 or its preparation components. Specifically, patients with a prior history of heparin induced thrombocytopenia or any other adverse reaction to heparin, will be excluded.
  26. The investigator believes that participating in the trial is not in the best interest of the patient, or the investigator considers patient unsuitable for enrollment (such as unpredictable risks or subject compliance issues).
  27. Positive for coronavirus disease (COVID)-19 by PCR or evidence of active infection per local institutional standards.
  28. Allergy to iodine contrast or anesthesia
  29. For female subjects: Pregnant, nursing, or planning to become pregnant during the course of entire duration of the study (approximately little over two years) or unwillingness to comply with contraceptive requirements.
  30. For male subjects: Male subjects with a female partner who is planning to become pregnant with the male subject during the entire course of the study or unwillingness to comply with contraceptive requirements.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    CELZ-201 Treatment Group

    Participants in this group will receive a single dose of CELZ-201, in addition to standard of care of care for Type 1 Diabetes treatment.

    Biological: CELZ-201 Administration

  • Placebo comparator
    Control Group

    Participants in this group will receive standard of care for Type 1 Diabetes only.

    Other: Control Group

Interventions

  • BiologicalCELZ-201 Administration

    Participants in this group will receive a single dose of CELZ-201, in addition to standard of care for Type 1 Diabetes treatment. Perinatal tissue derived cells will be administered at a dose of 1x10\^6 cells/kg via an intra-arterial infusion into the dorsal pancreatic artery.

  • OtherControl Group

    Enhanced standard of care for Type 1 Diabetes treatment only.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    The primary outcome to be assessed is tolerability and safety of the CELZ-201 therapy. The incidence of adverse events (grade 2 or above as per CTCAE version 5.0) in both groups at 6 months.

    Time frame: 6 months

Secondary outcomes

  1. Number of Participants with Adverse Events

    Incidence of adverse events (grade 2 or above as per CTCAE version 5.0) in both groups at 12 months.

    Time frame: 12 months

  2. Number of Participants with Adverse Events

    Incidence of adverse events (grade 2 or above as per CTCAE version 5.0) in both groups at 24 months.

    Time frame: 24 months

  3. Glycosylated HbA1C

    Changes in glycosylated HbA1c (%)

    Time frame: 12 months

  4. Insulin Requirement

    Changes in exogenous insulin requirement

    Time frame: 12 months

  5. Islet Autoantibody Levels

    Changes in islet autoantibody levels GAD65 (U/mL), IA2 (U/mL), and ZnT8 (U/mL)

    Time frame: 12 months

  6. Alloreactive Antibody Levels

    Changes in alloreactive antibody levels (U/mL)

    Time frame: 12 months

  7. C-peptide during a 4-hour MMTT

    Changes in fasting, peak stimulated and AUC C-peptide (ng/mL) during a 4-hour MMTT

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Diabetes Research Institute, University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
    Recruiting
    • Francesco Vendrame, MD · Contact(305) 243-5321
    • Francesco Vendrame, MD · Principal investigator
    • Rodolfo Alejandro, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jan 2027, 45 months after the start.

Of 44 phase 1/2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 93. This study's planned 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2022
First posted
Nov 25, 2022
StartActual
Apr 7, 2023
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2028
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05626712
Lead sponsor
Creative Medical Technology Holdings Inc
Responsible party
Sponsor
First posted
Nov 25, 2022
Start date
Apr 7, 2023
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Feb 19, 2026

Study contacts

Creative Medical Technology
Contact
clinicaltrials@creativemedicaltechnology.com
(702) 588-1890
Francesco Vendrame, MD
principal investigator · University of Miami, Diabetes Research Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion